Virax Biolabs Group Limited an innovative biotechnology company focused on immunology research and diagnostics, today published a shareholder letter from Chief Executive Officer James Foster and released an updated investor presentation. Together, these materials outline Virax's current strategic and commercial framework and the milestones management believes matter most over the next 90 to 180 days.
Highlights:
Large under-served category: Virax believes post-acute infection syndromes ("PAIS"), including Long COVID, post-treatment Lyme disease ("PTLD") and myalgic encephalomyelitis / chronic fatigue syndrome ("ME/CFS"), represent a large, under-served diagnostic category with no widely adopted objective test in major markets and an estimated U.S. economic burden in excess of $25 billion.
Our current focus: ViraxImmune™ is being developed to help identify immune dysfunction in PAIS using a novel, proprietary assay. Virax's current U.S. market-entry focus is a Laboratory Developed Test ("LDT") pathway, with broader in vitro diagnostic ("IVD") development intended to follow over time.
Next catalyst: Management views the planned PAIS data readout on assay performance as the next key milestone in validating ViraxImmune™ and informing the Company's next steps toward U.S. market entry. The investor presentation sets out a validation-led timeline with 2026 focused on readout and partner study preparation.
Operational progress: UK PAIS studies are fully recruited, the Company has completed its initial FDA pre-submission Q-Sub meeting and received feedback to inform strategy, U.S. clinical validation planning with Emory University is under way, and the Company has achieved ISO 13485 and ISO 9001 certification.
Balance sheet support: Virax remains debt-free and management believes the Company has resources to execute through key near-term milestones.
Valuation backdrop: Management expects Virax's unaudited cash position at March 31, 2026 to be approximately $6.4 million. As of April 10, 2026, Virax's market capitalisation was approximately $2.6 million, based on 19,923,432 outstanding shares. Management does not believe this valuation reflects the Company's debt-free balance sheet or progress toward key clinical and commercial milestones.
"Our task is to execute: advance the next phase of validation, continue building the U.S. market-entry pathway and let those milestones establish the Company's direction," said James Foster, Chairman and Chief Executive Officer of Virax Biolabs.
Virax is entering a more execution-focused phase. In a difficult small-cap market, our priority is to clarify the opportunity, deliver the next key data milestone and continue building toward a practical U.S. market-entry path.
Our near-term priorities are straightforward. We are concentrating the business on the areas we believe matter most to near-term value creation: a large under-served PAIS category with ViraxImmune™ as our lead product. An upcoming PAIS data readout will be an important milestone for ViraxImmune™ by helping assess whether the assay can distinguish immune dysfunction patterns in PAIS individuals relative to controls, and by informing the next phase of U.S. clinical validation planning.
Over the past year, we have worked to move ViraxImmune™ from concept toward clinical, regulatory and operational readiness. That has included recruitment across our UK PAIS studies, FDA pre-submission engagement, U.S. clinical validation planning and, most recently, the strengthening of our quality infrastructure through ISO 13485 and ISO 9001 certification. Together, these steps are intended to support disciplined assay development and the validation work needed for future market entry.
We continue to believe PAIS is a large, under-served diagnostic category with no widely adopted objective test in major markets. As our updated investor presentation sets out, millions of patients are affected, the estimated U.S. economic burden exceeds $25 billion, and the lack of objective testing continues to impair timely diagnosis, clinical management and therapeutic development. ViraxImmune™ is being developed to address that gap by helping identify immune dysfunction in PAIS through an objective test-based approach, which we believe could support clearer clinical assessment and treatment management over time. Against that backdrop, our objective is not to pursue every possible opportunity at once, but to focus on the indication, product and market-entry pathway we believe are most relevant to near-term value creation.
In the United States, our current focus is on an LDT pathway as the initial market-entry route, with broader IVD development to follow over time. We believe this may offer the most practical way to establish an initial commercial foothold while continuing to build the clinical and regulatory package required for broader adoption. Our investor presentation also sets out the intended coding and reimbursement progression, beginning with an initial miscellaneous-code billing approach and, over time, potentially moving toward a PLA code and broader permanent coding framework if clinical utility and market penetration are established.
Over the next 90 to 180 days, our priorities are clear: complete the rollout of our updated investor materials to improve communication of the Company's strategy and future potential to the market, deliver and contextualise the PAIS data readout, continue preparing the U.S. market-entry pathway, and use those milestones to support broader institutional and strategic engagement.
The next phase is about validation and preparation. The current milestone sequence is centred on 2026 validation activities and, over time, potential U.S. LDT market entry followed by broader IVD development.
Longer term, if the data and market engagement justify it, we believe this can support a broader value-creation path around ViraxImmune™ and the wider immune-profiling platform. For now, however, our focus is practical and near term: disciplined execution against defined milestones.
For more information, please visit www.viraxbiolabs.com
